ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE NONLYMPHOCYTIC LEUKEMIA

  • 1 January 1984
    • journal article
    • research article
    • Vol. 63  (3) , 649-656
Abstract
Seventy patients with acute nonlymphocytic leukemia (ANLL) underwent allogeneic bone marrow transplantation following cytoreduction with total body irradiation and cyclophosphamide. Thirty patients underwent transplantation in 1st remission, 11 in 2nd remission, 3 in 3rd remission and 26 in relapse. At a median follow-up of 30 mo., 17 of those in 1st remission and 7 of those in 2nd remission survive in continuous remission, compared to 1 in 3rd remission and 3 in relapse. The 3-yr Kaplan-Meier probability of disease-free survival among the various groups was 55% (.+-. 9.2%) for the 1st remission transplants, 64% (.+-. 14.5%) for 2nd remission, 33% (.+-. 20%) in 3rd remission and 10.3% (.+-. 6.3%) in the relapse group. Statistical analysis showed a similar survival in the 1st and 2nd remission groups that was significantly better than that seen in the 3rd remission and relapse groups (P < 0.01). The improved survival seen in the early remission groups was due to a significant decrease in the incidence of relapse posttransplant (P < 0.01). These results confirm observations that a significant number of patients transplanted in first remission may achieve extended disease-free survival and document similar results for patients transplanted in 2nd remission.

This publication has 0 references indexed in Scilit: